Company Biogen Inc.

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-12 pm EDT			5-day change	1st Jan Change
197.89 ^USD	-0.60%		-3.44%	-23.53%

Sep. 12	Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively	CI
Sep. 10	C4 Therapeutics Delivers Final Development Candidate Under Biogen Deal	MT

Business description: Biogen Inc.

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:

- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;

- royalties (17,2%) ;

- other (9,1%): primarily revenues from partnership agreements.

Number of employees: 7,570

Sales by Activity: Biogen Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Discovering, Developing and Delivering Worldwide Innovative Therapies	14.38B	13.44B	10.98B	10.17B	9.84B

See all business segments

Geographical breakdown of sales: Biogen Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
United States (U.S.)	9.51B	8.53B	5.83B	5.53B	5.43B
Europe	-	-	2.64B	2.41B	2.14B
Germany	-	-	1.16B	926M	868M
Asia	432M	630M	725M	720M	863M
Other	630M	619M	627M	583M	531M
Europe (Incl. Germany)	3.8B	3.66B	-	-	-

See all geographic segments

Managers: Biogen Inc.

Director	Title	Age	Since
Christopher Viehbacher CEO	Chief Executive Officer	64	22-11-13
Michael McDonnell DFI	Director of Finance/CFO	60	20-08-14
Nicole Murphy COO	Chief Operating Officer	-	14-12-31
Jane Grogan CTO	Chief Tech/Sci/R&D Officer	57	23-10-01
Chuck Triano IRC	Investor Relations Contact	-	23-04-09

See BIOGEN INC. governance

Members of the board: Biogen Inc.

Manager	Title	Age	Since
Caroline Dorsa CHM	Chairman	64	10-01-02
Eric Rowinsky BRD	Director/Board Member	67	10-03-19
Stephen Sherwin BRD	Director/Board Member	75	09-12-31
William Hawkins BRD	Director/Board Member	70	19-06-18
Jesus Mantas BRD	Director/Board Member	55	19-06-18
Maria Freire BRD	Director/Board Member	69	21-06-01
Christopher Viehbacher CEO	Chief Executive Officer	64	22-11-13
Susan Langer BRD	Director/Board Member	33	23-06-25
Monish Patolawala BRD	Director/Board Member	54	Dec. 31

Composition of the Board of Directors

Shareholders: Biogen Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 11.40 %	16,600,163	11.40 %	3 399 M $
PRIMECAP Management Co. 11.22 %	16,338,294	11.22 %	3 345 M $
BlackRock Advisors LLC 7.259 %	10,573,792	7.259 %	2 165 M $
STATE STREET CORPORATION 4.872 %	7,096,018	4.872 %	1 453 M $
T. Rowe Price Investment Management, Inc. 3.899 %	5,678,859	3.899 %	1 163 M $

Name	Equities	%	Valuation
Bram Bradesco Asset Management S/A DTVM 0.000003 %	30	0.000003 %	1 003 $

List of BIOGEN INC. shareholders

Holdings: Biogen Inc.

Name	Equities	%	Valuation
DENALI THERAPEUTICS INC. 8.91%	12,751,365	8.91%	311,643,361 $
SAGE THERAPEUTICS, INC. 10.22%	6,241,473	10.22%	52,615,617 $
SANGAMO THERAPEUTICS, INC. 1.56%	3,250,000	1.56%	2,756,000 $

Company details: Biogen Inc.

Biogen, Inc.

225 Binney Street

02142, Cambridge

+617 679 2000

http://www.biogen.com

Group companies: Biogen Inc.

Name	Category and Sector
Biogen MA, Inc. Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.	Biotechnology
Biogen International GmbH Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland.	Pharmaceuticals: Major

Name

Category and Sector

Biotechnology

Pharmaceuticals: Major

See all subsidiaries

Biopharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
BIOGEN INC.	-0.60%	-3.44%	-23.57%	-33.99%	29B
CSL LIMITED	+0.60%	-0.77%	+12.32%	-0.31%	96.47B
SAMSUNG BIOLOGICS CO.,LTD.	-1.02%	+2.64%	+32.29%	+4.97%	52.11B
UCB	+1.24%	-0.67%	+97.95%	+78.89%	33.66B
BIOMARIN PHARMACEUTICAL INC.	-0.47%	-6.10%	-7.13%	+8.21%	16.14B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.26%	-0.83%	+36.27%	-26.65%	12.27B
INCYTE CORPORATION	+0.36%	-1.51%	-1.63%	-10.91%	12.16B
ALTEOGEN INC.	+3.27%	+2.76%	+508.86%	+375.19%	12.13B
SWEDISH ORPHAN BIOVITRUM AB	+0.75%	+3.68%	+44.72%	+32.64%	10.51B
INNOVENT BIOLOGICS, INC.	-0.81%	0.00%	+12.14%	-33.10%	9.06B
Average	+0.21%	-0.50%	+71.22%	+39.49%	28.35B
Weighted average by Cap.	+0.18%	-0.95%	+44.26%	+21.75%